Clearance of S-(3-amino-2-hydroxypropyl) phosphorothioate (WR-77913) in rats

Tim T. Lam; David Liu; Michael A. Brody; Ralph Chu; Mark O.M. Tso

doi:10.1016/0014-4835(91)90018-A

Clearance of S-(3-amino-2-hydroxypropyl) phosphorothioate (WR-77913) in rats

Tim T. Lam, David Liu, Michael A. Brody, Ralph Chu, Mark O.M. Tso

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Complications of radiotherapy in the treatment of retinal and choroidal neoplastic diseases include cataract formation, radiation retinopathy, neovascular glaucoma, cystoid macular edema, and subretinal neovascularization. These side effects may be minimized by the use of compounds known to have a protective effect on normal ocular tissues without impeding the benefits of therapy. Phosphorothioates, first developed under the Antiradiation Drug Development Program of the U.S. Army Medical Research and Development Command, have been reported to protect normal tissues during radiation therapy in a variety of animal models. One of the phosphorothioates, WR-77913 (S-[3-amino-2-hydroxylpropyl] phosphorothioate) was found to inhibit cataract formation in rats after radiation exposure. To test the efficacy of WR-77913 in the retina, we established a high-pressure liquid chromatography method to measure the levels of dephosphorylated WR-77913 and studied the drug's clearance from the lens, retina, blood, kidney, and liver in rats.

Original language	English (US)
Pages (from-to)	661-667
Number of pages	7
Journal	Experimental eye research
Volume	52
Issue number	6
DOIs	https://doi.org/10.1016/0014-4835(91)90018-A
State	Published - Jun 1991
Externally published	Yes

Keywords

WR-77913
clearance
phosphorothioate
radioprotector
radiotherapy

ASJC Scopus subject areas

Ophthalmology
Sensory Systems
Cellular and Molecular Neuroscience

Access to Document

10.1016/0014-4835(91)90018-A

Cite this

@article{336db127fd9a426aae6e1bcb4bef4fc5,

title = "Clearance of S-(3-amino-2-hydroxypropyl) phosphorothioate (WR-77913) in rats",

abstract = "Complications of radiotherapy in the treatment of retinal and choroidal neoplastic diseases include cataract formation, radiation retinopathy, neovascular glaucoma, cystoid macular edema, and subretinal neovascularization. These side effects may be minimized by the use of compounds known to have a protective effect on normal ocular tissues without impeding the benefits of therapy. Phosphorothioates, first developed under the Antiradiation Drug Development Program of the U.S. Army Medical Research and Development Command, have been reported to protect normal tissues during radiation therapy in a variety of animal models. One of the phosphorothioates, WR-77913 (S-[3-amino-2-hydroxylpropyl] phosphorothioate) was found to inhibit cataract formation in rats after radiation exposure. To test the efficacy of WR-77913 in the retina, we established a high-pressure liquid chromatography method to measure the levels of dephosphorylated WR-77913 and studied the drug's clearance from the lens, retina, blood, kidney, and liver in rats.",

keywords = "WR-77913, clearance, phosphorothioate, radioprotector, radiotherapy",

author = "Lam, {Tim T.} and David Liu and Brody, {Michael A.} and Ralph Chu and Tso, {Mark O.M.}",

note = "Funding Information: This work was supported in part by the Morris Korzen amd Renee Izenman Memorial Foundation and grant DAMDl7-89-Z-9025 from the U.S. Army Medical Research and Development Command. We would like to thank Kathleen Louden and Mary Imhof for their editing and formatting assistance. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.",

year = "1991",

month = jun,

doi = "10.1016/0014-4835(91)90018-A",

language = "English (US)",

volume = "52",

pages = "661--667",

journal = "Experimental eye research",

issn = "0014-4835",

publisher = "Academic Press Inc.",

number = "6",

}

TY - JOUR

T1 - Clearance of S-(3-amino-2-hydroxypropyl) phosphorothioate (WR-77913) in rats

AU - Lam, Tim T.

AU - Liu, David

AU - Brody, Michael A.

AU - Chu, Ralph

AU - Tso, Mark O.M.

N1 - Funding Information: This work was supported in part by the Morris Korzen amd Renee Izenman Memorial Foundation and grant DAMDl7-89-Z-9025 from the U.S. Army Medical Research and Development Command. We would like to thank Kathleen Louden and Mary Imhof for their editing and formatting assistance. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.

PY - 1991/6

Y1 - 1991/6

N2 - Complications of radiotherapy in the treatment of retinal and choroidal neoplastic diseases include cataract formation, radiation retinopathy, neovascular glaucoma, cystoid macular edema, and subretinal neovascularization. These side effects may be minimized by the use of compounds known to have a protective effect on normal ocular tissues without impeding the benefits of therapy. Phosphorothioates, first developed under the Antiradiation Drug Development Program of the U.S. Army Medical Research and Development Command, have been reported to protect normal tissues during radiation therapy in a variety of animal models. One of the phosphorothioates, WR-77913 (S-[3-amino-2-hydroxylpropyl] phosphorothioate) was found to inhibit cataract formation in rats after radiation exposure. To test the efficacy of WR-77913 in the retina, we established a high-pressure liquid chromatography method to measure the levels of dephosphorylated WR-77913 and studied the drug's clearance from the lens, retina, blood, kidney, and liver in rats.

AB - Complications of radiotherapy in the treatment of retinal and choroidal neoplastic diseases include cataract formation, radiation retinopathy, neovascular glaucoma, cystoid macular edema, and subretinal neovascularization. These side effects may be minimized by the use of compounds known to have a protective effect on normal ocular tissues without impeding the benefits of therapy. Phosphorothioates, first developed under the Antiradiation Drug Development Program of the U.S. Army Medical Research and Development Command, have been reported to protect normal tissues during radiation therapy in a variety of animal models. One of the phosphorothioates, WR-77913 (S-[3-amino-2-hydroxylpropyl] phosphorothioate) was found to inhibit cataract formation in rats after radiation exposure. To test the efficacy of WR-77913 in the retina, we established a high-pressure liquid chromatography method to measure the levels of dephosphorylated WR-77913 and studied the drug's clearance from the lens, retina, blood, kidney, and liver in rats.

KW - WR-77913

KW - clearance

KW - phosphorothioate

KW - radioprotector

KW - radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0025829378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025829378&partnerID=8YFLogxK

U2 - 10.1016/0014-4835(91)90018-A

DO - 10.1016/0014-4835(91)90018-A

M3 - Article

C2 - 1649765

AN - SCOPUS:0025829378

SN - 0014-4835

VL - 52

SP - 661

EP - 667

JO - Experimental eye research

JF - Experimental eye research

IS - 6

ER -

Clearance of S-(3-amino-2-hydroxypropyl) phosphorothioate (WR-77913) in rats

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this